DIA-MHRA Summit Focuses on Faster Patient Access - EMJ

This site is intended for healthcare professionals

Experts Want Faster Patient Access to Treatment – DIA-MHRA Summit

Author:
DIA-MHRA Global Summit

Key Summary:

  • Earlier trial participation and coordinated regulation could help treatments reach patients sooner.
  • AI and linked health data offer opportunities to improve research, recruitment and development.
  • Prevention and international collaboration were recurring priorities for sustainable healthcare innovation.

FASTER patient access to innovative treatments, stronger international regulatory cooperation and a greater focus on disease prevention were central themes at the inaugural DIA-MHRA Global Summit.

Held at Senate House, University of London, on 16 and17 November 2026, the event brought together regulators, healthcare professionals, researchers, industry leaders and patient representatives under the theme, ‘Global Collaboration for Safer and Smarter Health Innovation’.

Across the meeting, discussions explored how research, regulation and healthcare delivery must evolve together to ensure that scientific advances translate into accessible, affordable care.

Prevention Must Accompany Longer Lives

Professor Sir John Bell, Chair of Our Future Health, described the current period as “the golden age of biomedicine”, while warning that improvements in longevity had not been matched by equivalent gains in healthy life.

“But while life expectancy has risen, healthspan has not at all,” he said, arguing that healthcare must place greater emphasis on preventing illness.

Looking ahead, Bell said: “the next 20 years have to focus on preventing disease.”

Sir Jonathan Symonds, Chair of GSK, echoed concerns about the distinction between living longer and living in good health. “In the UK, the gap between lifespan and healthspan is widening,” he said.

These remarks highlighted the importance of identifying and addressing risks earlier before patients develop chronic disease, alongside developing treatments for established disease.

For clinicians, this places prevention and earlier intervention at the centre of discussions about innovation and sustainable care.

Bringing Clinical Trials to Patients Earlier

Discussions also highlighted the need to shorten the development pathway, from identifying and enrolling eligible patients to completing trials and making treatments available in routine care.

Dr Ravi Rao, Chief Medical Officer, Sitryx, said that “people want to take part in trials”, identifying the challenge as reaching potential participants and enabling their involvement.

He also questioned the tendency to consider trial participation only after other treatment options have been exhausted.

“This is a flawed approach, so we need to be getting it to patients much sooner before the disease has evolved,” he said.

His comments highlighted the need to consider research participation earlier in the patient pathway, rather than primarily when few alternatives remain.

The programme also examined the relationship between regulatory approval, NHS adoption and healthcare capacity, recognising that authorisation alone does not ensure access.

Earlier engagement between developers, regulators and healthcare systems could help address barriers throughout development.

Using AI and Data to Accelerate Research

Professor Francesco Saverio Tedesco, Associate Research Director and Principal Group Leader at the Francis Crick Institute, and Professor at UCL, highlighted the potential of emerging technologies to support faster research.

“We have the opportunity in the use of AI and modelling to help with this. We need to find a way to speed up the process even more so that we can start trials even faster,” he said.

AI, improved data collection and regulatory sandboxes were prominent themes. Sandboxes provide supervised environments in which emerging approaches can be explored, helping developers and regulators understand practical challenges.

Sessions considered AI-enabled drug repurposing and computer-based modelling, including digital twins and synthetic datasets, alongside the scientific and regulatory questions surrounding their use.

Better use of linked clinical information could support patient identification, trial recruitment and the monitoring of treatment outcomes. Consistent data collection and standardised processes were recurring priorities for connecting research with clinical practice.

Building International Regulatory Pathways

International cooperation was another recurring theme, with discussions examining how countries can learn from one another and develop more coordinated approaches to healthcare innovation.

Lord David Willetts, Chair of the Regulatory Innovation Office and President of the Resolution Foundation, highlighted the lessons that larger nations could draw from smaller systems.

“Medium and large sized countries can learn from smaller countries about collaboration and improvisation,” he said.

Dr Maria Vassileva, Chief Scientific and Regulatory Officer, DIA, similarly emphasised the importance of cooperation between regulators in enabling innovation.

“We are citizens of this country but we are also citizens of the world,” she said, highlighting the international perspective needed when considering advances in healthcare.

The programme explored how regulatory alignment and collaborative pathways could reduce duplication and improve efficiency, while maintaining confidence in regulatory decisions.

Translating Genomics into Rare Disease Treatments

Rare diseases illustrated the urgency of linking scientific capability with treatment access. Genomic sequencing can help identify disease-causing variants, but diagnosis must be accompanied by routes to develop and deliver appropriate therapies.

Former UK Prime Minister Sir David Cameron and Julia Vitarello, Founder of Mila’s Miracle Foundation Inc., called for changes to support individualised medicines and more scalable development of treatments for rare diseases.

“Science isn’t the limiting factor anymore, right? We have the science to do this,” Vitarello said, arguing that access arrangements must keep pace with scientific advances.

Making Innovation Affordable and Sustainable

Medication costs and the economic implications of treatment access were further priorities. More efficient development must be accompanied by sustainable funding, manufacturing capacity and healthcare delivery.

Together, these discussions connected two ambitions: enabling patients with existing disease to benefit from innovation sooner,  and intervening earlier to reduce future illness.

Achieving both, it was clear throughout the event, will require sustained cooperation across clinicians, researchers, regulators, industry and healthcare systems and a willingness by all to push towards faster and more efficient innovation and drug development.

Featured image: metamorworks on AdobeStock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.